Updated Jul 16, 2026
ADAR1 Capital Management, LLC has filed 5 SEC Form 4 filings across 2 companies in the last 90 days — active on both sides. Lifetime open-market purchases: $4.95M. Lifetime open-market sales: $95.66M.
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-21 | INM | InMed Pharmaceuticals Inc. | P — Open-market purchase | 200.0K | $1.50 | $300K |
| 2026-05-21 | INM | InMed Pharmaceuticals Inc. | P — Open-market purchase | 200.0K | $1.56 | $312K |
| 2026-05-21 | INM | InMed Pharmaceuticals Inc. | P — Open-market purchase | 68.6K | $1.60 | $110K |
| 2026-05-21 | RLYB | Rallybio Corp | P — Open-market purchase | 200 | $13.80 | $3K |
| 2026-05-21 | RLYB | Rallybio Corp | P — Open-market purchase | 10.0K | $13.98 | $140K |
| 2026-05-21 | RLYB | Rallybio Corp | P — Open-market purchase | 6.0K | $13.98 | $84K |
| 2026-05-16 | RLYB | Rallybio Corp | P — Open-market purchase | 200 | $13.95 | $3K |
| 2026-05-16 | RLYB | Rallybio Corp | P — Open-market purchase | 100 | $13.80 | $1K |
| 2026-05-16 | RLYB | Rallybio Corp | P — Open-market purchase | 75.2K | $14.00 | $1.05M |
| 2026-05-16 | RLYB | Rallybio Corp | P — Open-market purchase | 4.1K | $13.80 | $56K |
| 2026-05-14 | RLYB | Rallybio Corp | P — Open-market purchase | 800 | $13.83 | $11K |
| 2026-05-14 | RLYB | Rallybio Corp | P — Open-market purchase | 19.9K | $14.00 | $279K |
| 2026-05-14 | RLYB | Rallybio Corp | P — Open-market purchase | 25.0K | $14.00 | $350K |
| 2026-05-14 | RLYB | Rallybio Corp | P — Open-market purchase | 5.1K | $14.00 | $71K |
| 2026-05-07 | RLYB | Rallybio Corp | P — Open-market purchase | 35.1K | $14.00 | $491K |
| 2026-05-07 | RLYB | Rallybio Corp | P — Open-market purchase | 116.9K | $13.97 | $1.63M |
| 2026-05-07 | RLYB | Rallybio Corp | P — Open-market purchase | 3.9K | $13.90 | $54K |
| 2025-10-15 | KROS | Keros Therapeutics, Inc. | S — Open-market sale | 743.4K | $17.75 | $13.19M |
| 2025-10-15 | KROS | Keros Therapeutics, Inc. | S — Open-market sale | 254.7K | $17.75 | $4.52M |
| 2025-10-15 | KROS | Keros Therapeutics, Inc. | S — Open-market sale | 4.39M | $17.75 | $77.94M |
ADAR1 Capital Management, LLC is a corporate insider — currently tracked as 10% Owner of InMed Pharmaceuticals Inc. (INM). InsiderAlpha tracks every SEC Form 4 filing in real time.
5 primary Form 4 filings in the last 90 days, covering 2 companies.
Recorded transactions: 17 open-market purchases ($4.95M) and 3 open-market sales ($95.66M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live ADAR1 Capital Management, LLC profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.